XELLIA PHARMACEUTICALS USA, LLC

DAPTOMYCIN

Manufacturer:

XELLIA PHARMACEUTICALS USA, LLC

Daptomycin HCPCS:

J0873

HCPCS Code Descriptor:

Injection, daptomycin (xellia) not therapeutically equivalent to j0878, 1 mg

Category:

J Code

Daptomycin NDCs:

70594-0053-01

Primary Type:

Antibiotic

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Daptomycin:

DAPTOMYCIN is a Antibiotic drug manufactured by XELLIA PHARMACEUTICALS USA, LLC and administered via the Intravenous route of administration. The J Code: J0873 is aligned to the drug DAPTOMYCIN.

Daptomycin is an antibiotic that is often used to treat a variety of different bacterial infections. Daptomycin can treat complicated bacterial infections in the skin and underlying tissues, as well as infections that have entered the bloodstream. It treats infections caused by Gram-positive bacteria, such as MRSA and VRE.

ACCESS PRICING AND MORE BY REGISTERING

J0873 Added Date:

January 1, 2024

J0873 Effective Date:

January 1, 2024

J0873 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Daptomycin billing and coding information.
Our team did not identify a source for Daptomycin patient assistance information. Please reach out to our team if you feel that this is a mistake.
DAPTOMYCIN prescribing information can be found at the link below:
Information regarding DAPTOMYCIN’s side effects can be found at MedlinePlus